[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3638251T3 - BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF - Google Patents

BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF Download PDF

Info

Publication number
DK3638251T3
DK3638251T3 DK18816615.1T DK18816615T DK3638251T3 DK 3638251 T3 DK3638251 T3 DK 3638251T3 DK 18816615 T DK18816615 T DK 18816615T DK 3638251 T3 DK3638251 T3 DK 3638251T3
Authority
DK
Denmark
Prior art keywords
bisphosphocine
gel formulations
formulations
gel
bisphosphocine gel
Prior art date
Application number
DK18816615.1T
Other languages
Danish (da)
Inventor
Steven A Kates
Keith Arthur Johnson
Original Assignee
Lakewood Amedex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakewood Amedex Inc filed Critical Lakewood Amedex Inc
Application granted granted Critical
Publication of DK3638251T3 publication Critical patent/DK3638251T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Ophthalmology & Optometry (AREA)
DK18816615.1T 2017-06-12 2018-06-12 BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF DK3638251T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518262P 2017-06-12 2017-06-12
PCT/US2018/037151 WO2018231863A1 (en) 2017-06-12 2018-06-12 Bisphosphocin gel formulations and uses thereof

Publications (1)

Publication Number Publication Date
DK3638251T3 true DK3638251T3 (en) 2024-05-13

Family

ID=64562861

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18816615.1T DK3638251T3 (en) 2017-06-12 2018-06-12 BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF

Country Status (14)

Country Link
US (4) US11096954B2 (en)
EP (2) EP4241769A3 (en)
JP (2) JP7148994B2 (en)
KR (2) KR20200014904A (en)
CN (1) CN110753549A (en)
AU (3) AU2018282905B2 (en)
BR (2) BR122021011439B1 (en)
CA (1) CA3066722A1 (en)
DK (1) DK3638251T3 (en)
ES (1) ES2981923T3 (en)
FI (1) FI3638251T3 (en)
MX (1) MX2019014772A (en)
PT (1) PT3638251T (en)
WO (1) WO2018231863A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5887044B2 (en) 2005-04-15 2016-03-16 クラルス セラピューティクス, インコーポレーテッドClarus Therapeutic, Inc. Hydrophobic drug delivery system and composition thereof
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11377468B2 (en) 2017-03-10 2022-07-05 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
EP4272832A3 (en) * 2017-03-10 2023-11-22 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
BR122021011439B1 (en) 2017-06-12 2022-03-29 Lakewood Amedex, Inc Bisphosphocine gel formulation and uses
CN112839662A (en) * 2018-10-17 2021-05-25 莱克伍德阿美达克斯股份有限公司 Methods and compositions for treating oral mucositis
US20230092578A1 (en) * 2021-07-22 2023-03-23 Lakewood Amedex, Inc. Methods for preparing bisphosphocins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
SE8004580L (en) * 1980-06-19 1981-12-20 Draco Ab PHARMACEUTICAL PREPARATION
KR830005852A (en) * 1980-07-18 1983-09-14 미첼 페터 잭슨 Preparation of topical treatments suitable for the treatment of viral infections on skin and mucous membranes
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
DE3542516A1 (en) 1985-12-02 1987-06-04 Henkel Kgaa DISINFECTANT
US5266310A (en) 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3731255A1 (en) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilization of therapeutically active proteins in pharmaceutical preparations
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US5167950A (en) * 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
US5208015A (en) * 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
DE4333385C2 (en) 1993-09-30 1997-01-30 Friedrich A Spruegel Surface disinfectants and cleaning agents
CZ267396A3 (en) * 1994-03-11 1997-03-12 Procter & Gamble HYDROLYTIC STABLE COSMETIC, PREPARATION WITH LOW pH VALUE CONTAINING ACID ACTIVE SUBSTANCES
FR2718022B1 (en) 1994-04-01 1996-04-26 Roussel Uclaf Cosmetic or dermatological compositions and their preparation.
FR2722102B1 (en) * 1994-07-11 1996-08-23 Cird Galderma USE OF DEFORMABLE HOLLOW PARTICLES IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING FAT MATERIALS
US5843998A (en) 1997-06-30 1998-12-01 Song; Jin Skin blemish treatment
US6627215B1 (en) 1998-12-30 2003-09-30 Oligos Etc. Inc. Devices for improved wound management
US7868162B2 (en) * 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
AU2002337862A1 (en) * 2001-10-18 2003-04-28 Ilex Products, Inc. Methods of treating skin with diphosphonate derivatives
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
CN1687100A (en) * 2005-04-05 2005-10-26 奥林格斯技术有限公司 Modification nucleotide and its use
EP2149375A1 (en) 2008-07-28 2010-02-03 Despharma Kft. Compositions for the treatment of dermatological diseases, and uses thereof
JP5205549B2 (en) 2009-04-13 2013-06-05 スラー サブラマニアン ヴァナンガムディ Medicinal fusidic acid cream produced using sodium fusidate and incorporating a biopolymer, and method for producing the same
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
FR3041540B1 (en) 2015-09-29 2018-10-26 Galderma Research & Development SELF-MOUSING CLEANING COMPOSITION FOR RINSING, CONTAINING IVERMECTIN.
BR122021011439B1 (en) 2017-06-12 2022-03-29 Lakewood Amedex, Inc Bisphosphocine gel formulation and uses

Also Published As

Publication number Publication date
EP3638251A4 (en) 2021-03-10
JP2022183154A (en) 2022-12-08
EP4241769A3 (en) 2023-11-08
US20210361689A1 (en) 2021-11-25
AU2018282905A1 (en) 2019-12-19
US20180353529A1 (en) 2018-12-13
JP2020523322A (en) 2020-08-06
US11096954B2 (en) 2021-08-24
CN110753549A (en) 2020-02-04
WO2018231863A1 (en) 2018-12-20
US20200360415A1 (en) 2020-11-19
EP4241769A2 (en) 2023-09-13
JP7148994B2 (en) 2022-10-06
AU2024202211A1 (en) 2024-05-02
MX2019014772A (en) 2020-02-07
CA3066722A1 (en) 2018-12-20
EP3638251B1 (en) 2024-03-06
EP3638251A1 (en) 2020-04-22
US20230125677A1 (en) 2023-04-27
BR112019026073B1 (en) 2021-11-03
ES2981923T3 (en) 2024-10-11
AU2022224829B2 (en) 2024-12-05
FI3638251T3 (en) 2024-04-29
KR20230031370A (en) 2023-03-07
US12156883B2 (en) 2024-12-03
BR112019026073A2 (en) 2020-06-30
KR20200014904A (en) 2020-02-11
AU2018282905B2 (en) 2022-06-02
JP7470449B2 (en) 2024-04-18
AU2022224829A1 (en) 2022-09-29
PT3638251T (en) 2024-05-22
BR122021011439B1 (en) 2022-03-29

Similar Documents

Publication Publication Date Title
DK3784283T3 (en) CANNABIDIO PREPARATIONS AND USES THEREOF
DK3638251T3 (en) BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF
DK3478811T3 (en) Cleaning compositions and uses thereof
DK3658557T3 (en) TYK2 INHIBITORS AND USES THEREOF
DK3448386T3 (en) ISOQUINOLIN-3-YLCARBOXAMIDES AND MANUFACTURE AND USE THEREOF
DK3607069T3 (en) Products and compositions
DK3610005T3 (en) PEPTIDLIGASE AND ITS USE
DK3485010T3 (en) BACILLUS CIBI DNASE VARIANTS AND USES THEREOF
DK3668512T3 (en) PYRUVACKINASE MODULATORS AND USES THEREOF
DK3452463T3 (en) AMID-SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF
DK3580561T3 (en) HLA-BASED METHODS, COMPOSITIONS AND USES THEREOF
DK3357513T3 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
DK3655401T3 (en) TLR7/8 ANTAGONISTS AND USES THEREOF
DK3557998T3 (en) COMPOSITIONS, COMPOSITIONS AND METHODS OF USE
DK3430129T5 (en) COLONY-FORMING MEDIUM AND USE THEREOF
DK3423076T3 (en) TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF
DK3536698T3 (en) LANOSTEROL PRODUCT COMPOUND AND USE THEREOF
DK3621694T5 (en) LRRC33 INHIBITORS AND USES THEREOF
DK3692009T3 (en) BIOCEMENTATION PROCEDURE AND SYSTEM
DK3612579T3 (en) PULTRUDATE, MANUFACTURE AND USE thereof
DK3420039T3 (en) PRINTING FORMULATIONS AND METHODS
DK3743106T3 (en) INFLUENZAVIRUS VACCINES AND USES THEREOF
DK3615502T3 (en) THERAPEUTIC COMPOUNDS AND METHODS
EP3758712A4 (en) CPG-AMPHIPHILES AND USES THEREOF
DK3321279T3 (en) EXENATID MODIFICANT AND USE THEREOF